FDA gives full approval to a drug designed to slow Alzheimer’s disease

The Food and Drug Administration on Thursday gave its approval to Leqembi, a drug designed to slow the progression of Alzheimer’s disease. Leqembi is not considered a cure for Alzheimer’s, but will be covered by Medicare. Dr. Jon LaPook has more. Source